NNNN Anbio Biotechnology
Fundamentals / CIK 0001982708 / USDAnbio Biotechnology reported $8.65M in revenue and net income of $6.40M for the fiscal year ended December 31, 2025 (up 5.6% year over year), with a 87.2% gross margin and a 66.7% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open NNNN in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$8.65M +5.6% YoY
-
Operating Income FY 2025$5.77M 66.7% margin
-
Net Income FY 2025$6.40M 74.1% net margin
-
Diluted EPS FY 2025$0.15 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Dec 31, 2025$11.90M Total debt: --
Annual revenue and net income
4 fiscal years (2022 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of Revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| Gross Profit | $7.54M | $5.89M | $3.36M | $12.56M |
| Research & Development | $201K | $454K | $135K | $200K |
| Selling, General & Admin | $1.57M | $3.44M | $1.27M | $2.17M |
| Total Operating Expenses | $1.78M | $3.89M | $1.40M | $2.37M |
| Operating Income | $5.77M | $2.00M | $1.96M | $10.20M |
| Interest Income | $142K | $338K | $165K | $42K |
| Interest Expense | -- | -- | -- | $8.0K |
| Income Before Tax | $6.40M | $2.37M | $2.25M | $10.01M |
| Income Tax Expense | $0 | $0 | $0 | -- |
| Net Income | $6.40M | $2.37M | $2.25M | $10.01M |
| Basic EPS | $0.15 | $0.06 | $0.10 | $100,112.00 |
| Diluted EPS | $0.15 | $0.06 | $0.10 | $100,112.00 |
| Basic Shares Outstanding | 43.7M | 42.3M | 21.4M | 100 |
| Diluted Shares Outstanding | 43.7M | 42.3M | 21.4M | -- |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & Cash Equivalents | $7.77M | $11.76M | $9.69M |
| Short-Term Investments | $4.13M | $0 | -- |
| Cash & Short-Term Investments | $11.90M | $11.76M | $9.69M |
| Accounts Receivable, Net | $3.66M | $1.06M | $1.88M |
| Other Current Assets | $14.08M | $5.68M | -- |
| Total Current Assets | $30.24M | $18.53M | $15.75M |
| Total Non-Current Assets | $0 | $387K | $62K |
| Total Assets | $30.24M | $18.92M | $15.81M |
| Accounts Payable | $0 | $1.63M | $827K |
| Other Current Liabilities | $88K | $105K | $166K |
| Total Current Liabilities | $88K | $1.73M | $993K |
| Total Non-Current Liabilities | $0 | $0 | $0 |
| Total Liabilities | $88K | $1.73M | $993K |
| Retained Earnings | $23.58M | $17.17M | $14.80M |
| Total Stockholders' Equity | $30.16M | $17.19M | $14.82M |
| Total Equity | $30.16M | $17.19M | $14.82M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $7.77M | $11.76M | $9.69M |
| Short-Term Investments | $4.13M | $0 | -- |
| Cash & Short-Term Investments | $11.90M | $11.76M | $9.69M |
| Accounts Receivable, Net | $3.66M | $1.06M | $1.88M |
| Other Current Assets | $14.08M | $5.68M | -- |
| Total Current Assets | $30.24M | $18.53M | $15.75M |
| Total Non-Current Assets | $0 | $387K | $62K |
| Total Assets | $30.24M | $18.92M | $15.81M |
| Accounts Payable | $0 | $1.63M | $827K |
| Other Current Liabilities | $88K | $105K | $166K |
| Total Current Liabilities | $88K | $1.73M | $993K |
| Total Non-Current Liabilities | $0 | $0 | $0 |
| Total Liabilities | $88K | $1.73M | $993K |
| Retained Earnings | $23.58M | $17.17M | $14.80M |
| Total Stockholders' Equity | $30.16M | $17.19M | $14.82M |
| Total Equity | $30.16M | $17.19M | $14.82M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Net Income | $6.40M | $2.37M | $2.25M | $10.01M |
| Change in Receivables | -$2.59M | $820K | -$1.88M | $718K |
| Change in Inventory | -- | -- | $354K | -$354K |
| Change in Payables | -$1.63M | $798K | -$581K | -$482K |
| Operating Cash Flow | -$6.74M | $2.08M | $898K | $4.45M |
| Purchases of Investments | -- | -$35.47M | -$18.54M | -$16.09M |
| Investing Cash Flow | -$4.20M | $337K | $1.73M | -$1.53M |
| Common Stock Issued | $7.23M | $0 | $0 | -- |
| Financing Cash Flow | $6.95M | -$345K | -$43K | -- |
| Net Change in Cash | -$3.99M | $2.07M | $2.59M | $2.92M |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Gross Margin | 87.2% | 71.9% | 50.1% | 53.4% |
| Operating Margin | 66.7% | 24.4% | 29.2% | 43.3% |
| Net Profit Margin | 74.1% | 29.0% | 33.6% | 42.5% |
| Return on Equity (ROE) | 21.2% | 13.8% | 15.2% | -- |
| Return on Assets (ROA) | 21.2% | 12.5% | 14.3% | -- |
| Current Ratio | 344.31x | 10.71x | 15.86x | -- |
| Quick Ratio | 177.12x | 7.41x | 11.65x | -- |
| Revenue Growth (YoY) | +5.6% | +21.9% | -71.5% | -- |
| Gross Profit Growth (YoY) | +28.2% | +75.1% | -73.2% | -- |
| Operating Income Growth (YoY) | +189.1% | +1.8% | -80.8% | -- |
| Net Income Growth (YoY) | +169.9% | +5.3% | -77.5% | -- |
| EPS Growth (YoY) | +162.5% | -46.7% | -100.0% | -- |
| Operating Cash Flow Growth (YoY) | -423.9% | +131.6% | -79.8% | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.